Cardiac amyloidosis (CA) is caused by the accumulation of amyloid
fibrils in the extracellular space of the myocardium, leading to clinical
manifestations that include conduction disturbances and heart
failure. CA was traditionally considered a rare disease with no effective
therapies and a poor prognosis. In recent years, more options for
non-invasive diagnosis and greater disease awareness have led to the
identification of a growing number of cases, challenging the notion of
CA as a rare disorder. The ability of recognizing and managing patients
with CA should become part of the core curriculum of Cardiologists
as well as Internal Medicine specialists, General Practitioners,
Neurologists, Nephrologists and Hematologists.
The Pisa Amyloid 2022 meeting will gather international experts
of CA to the city of the leaning tower and will represent a unique
opportunity to learn about CA for all audiences, as it will span from
basic knowledge about CA to the forefront of scientific research.
Michele Emdin, Claudio Passino,
Claudio Rapezzi, Giuseppe Vergaro